Anika Therapeutics' CEO Discusses Q2 2012 Earnings Results - Earnings Call Transcript

Anika Therapeutics, Inc. (ANIK)

Q2 2012 Earnings Call

August 2, 2012 9:00 am ET


Kevin W. Quinlan – Chief Financial Officer, Treasurer & Secretary

Charles H. Sherwood, Ph. D. – President, Chief Executive Officer & Director


Jim Gentrup – Discovery Investments

Greg Garner – Singular Research

Andre Thomas – Summer Street Research



Welcome to the second quarter 2012 Anika Therapeutics investor conference call. At this time all participants are in a listen only mode. We will conduct a question and answer session towards the end of this conference. (Operator Instructions) As a reminder, this call is being recorded for replay purposes. I will now turn the call over to Mr. Kevin Quinlan, Anika’s Chief Financial Officer.

Kevin W. Quinlan

If you have not received a copy of the Anika news release which was issued yesterday after the market closed or you would like to be added to our contact list, please contact Sharon Merrill Associates at 617-542-5300. The news release is posted in the investor relations section of our website at In addition, the slide presentation is posted on the Anika website that illustrates some of the points that we’ll be covering during today’s call. The slides can be found on the investor relations section under the events, webcasts, and presentations tab. We invite you to take a moment to open the file and follow the presentation along with us.

Please turn to Slide Number Two. Before we begin please remember that the statements made in this call which are not statements of historical fact are forward-looking statements as defined in the Securities Exchange Act of 1934. Words such as will, believe, appear, plan, expect, anticipate, forward, seek, continue, target, goals, objectives, on track, intend, pursue, outlook, as well as other expressions which are predictions or indications of future events or trends and which do not constitute historical matters identify forward-looking statements.

If you liked this article you might like

Biotech Movers: Anika Up on Strong Analyst Ratings

'Mad Money' Lightning Round: Smith and Wesson Represents Value, Cramer Says

Jim Cramer's 'Mad Money' Recap: How Powerful Are GE, Royal Dutch Shell and Occidental?

Here's Whats Next for Anika Therapeutics Post-Breakout